LifeStance Health Group Inc. reported third quarter 2025 revenue of $363.8 million, up 16% from the prior year, driven by increased visit volumes from net clinician growth and improved clinician productivity. Net income for the quarter was $1.1 million, compared to a net loss of $6.0 million in the previous year. Center Margin rose 16% to $116.6 million, representing 32.0% of total revenue. Adjusted EBITDA increased 31% to $40.2 million, or 11.1% of total revenue. Cash flow from operations for the quarter was $27.3 million, with a cash balance of $203.9 million and net long-term debt of $269.4 million at quarter end. The company reported free cash flow of $17.0 million. LifeStance reiterated its full year 2025 revenue guidance of $1.41 billion to $1.43 billion, raised its Center Margin midpoint expectations to $448 million to $462 million, and increased its Adjusted EBITDA guidance to $146 million to $152 million. The company also noted 17% organic visit growth and a clinician team of approximately 8,000 as key business developments for the period.